Post-earnings recap
Reported
Mon, Oct 28, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The strong EPS figure indicates that CRISPR Therapeutics is performing well financially, which likely contributed to the 12.55% increase in stock price. Investors may be encouraged by the company's advancements in gene editing, despite the lack of revenue details and future guidance. Overall, the positive sentiment reflects confidence in the company's growth potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.40 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed enthusiasm about the advancements in their gene editing technology. They emphasized their commitment to developing innovative treatments.
We are excited about our progress in gene editing.
Our focus remains on advancing our pipeline.